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Introduction
Phyllodes tumours (PT) are infrequent tumours occur-
ring in the breast with an incidence of less than 1% of all
breast tumours.1 Though there are specific laid down cri-
teria for diagnosing these cases, making a definite preop-
erative diagnosis is still difficult. Difficulty in making
preoperative diagnoses and concern for uncertain clinical
behaviour often results in inappropriate management of
many patients with PT.1,2 One of the characteristic 
uncertainties about these tumours is the unpredictable
risk of recurrence plaguing the clinical course of the disease.
None of the clinicopathological factors have consistently
been proven to be risk factors for recurrence and mortality
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BACKGROUND: The aim of this study was to present our experience of dealing with patients with phyl-
lodes tumours (PT) and to correlate the risk of local recurrence with different clinicopathological factors.
MATERIALS AND METHODS: This was a retrospective study of 25 women with PT, who were man-
aged at our centre between 1991 and 2005. All the available clinical, operative and histological details
were retrieved. The median follow-up period was 4 years (range, 1–9 years). Various clinicopathological
features were compared between patients who suffered from recurrent tumours to those not experiencing
any recurrence.
RESULTS: The mean age of the patients was 45 ± 7 years and the mean duration of symptoms was 30 ± 10
months. The mean tumour diameter was 10.5 ± 5 cm. Preoperative diagnosis with fine needle aspiration
cytology could be made in 72% of cases. Overall, 39 surgical procedures were performed (14 of which were
performed for recurrences). The histology report was benign, borderline and malignant PT in 28%, 20%
and 52% of cases respectively. Recurrent tumours were observed in 36% of patients and 16% experienced
more than one recurrence. Two patients with malignant PT developed metastases in the follow-up period,
and one of them died. Except for the extent of primary surgery, there were no significant differences in
other clinicopathological factors between the recurrent and non-recurrent groups. Patients who had wide
local excision (WLE) and procedures of greater magnitudes as primary procedures did not experience
recurrence (p = 0.008). However, when WLE was performed for recurrent tumours, 50% of patients 
suffered from recurrence.
CONCLUSION: WLE seems to be the initial procedure of choice for all PTs, and mastectomy for recurrent
tumours. Further studies are needed to define the role of adjuvant therapies. [Asian J Surg 2009;
32(4):224–8]
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so far. Surgery remains the mainstay of management, 
and the role of adjuvant therapy remains controversial.
Recommended surgical options vary from wide local exci-
sion (WLE) to mastectomy. The majority of physicians
currently suggest that irrespective of the pathology of PT
(benign, borderline or malignant), WLE is an appropriate
and adequate primary surgical intervention and a mastec-
tomy is rarely required.1–3 The aim of this study was to
present our experience of dealing with patients with PT
and to correlate the risk of local recurrence with different
clinicopathological factors.
Materials and Methods
This was a retrospective study of 25 women with PT, who
were managed between January 1991 and December 2006
at a tertiary referral centre in Northern India. In all
included cases, histological diagnosis of PT was docu-
mented. All the demographic, clinical, investigational,
operative and histology records were collected from the
inpatient departmental database. Follow-up data were
collected from the outpatient follow-up register and in a
few cases by contacting patients by mail and telephone.
WLE was when a tumour was excised with a minimum of
a 1 cm margin from the palpable tumour. Simple local
excision (LE) was when no attempt at WLE was made and
margins were inadequate. Various clinicopathological fea-
tures including the type of surgical intervention were
compared between patients experiencing local recurrence
to those not experiencing any recurrence. Statistical analy-
sis was done using Student’s t test, the Chi-square test,
binary logistic regression and multivariate analysis on
SPSS version 10 (SPSS Inc., Chicago, IL, USA). A p value
of less than 0.05 was considered significant for all the
tests.
Results
The mean age of the 25 patients was 45 ± 7 years (range,
20–75 years). The mean duration of having a lump was
30 ± 10 (2–240) months. All cases presented with large
lump. The mean tumour diameter was 10 ± 5 (5–20) cm.
One woman presented with bilateral PT. Two patients
had ulcers overlying the lump. Palpable axillary lymph
nodes were present in seven cases. Out of the 25 cases, 19
(76%) patients presented with primary disease and six
(24%) patients presented after experiencing recurrence.
Three cases reported to us after experiencing more than
one recurrence. The primary surgical procedures in recurrent
cases were mostly performed at peripheral hospitals and
since fine needle aspiration cytology (FNAC) was not
available at most of these peripheral hospitals, the attend-
ing surgeon performed operations as though these were
fibroadenoma and a diagnosis of PT could not be made
in the preoperative period. The reported final histological
diagnosis in these six cases were: one fibroadenoma, one
fibroadenosis, one giant fibroadenoma, two epithelial
hyperplasia, and one PT (malignant potential not speci-
fied). No tissue or slides were available for review. The
three recurrent patients initially operated on at our cen-
tre were reported as having giant fibroadenoma in one
case and benign PT in the other two cases. All patients
were subsequently subjected to FNAC. Preoperative diag-
nosis of PT could be made in 18 (72%) cases. Details of
clinical characteristics, pathology and surgical interven-
tions are summarised in Table 1.
Overall, 39 surgical procedures were performed, inclu-
ding 25 for primary tumours and 14 for recurrences. 
Table 1. Summary of clinicopathological features
Clinical/pathological factors n (%)
Age (yr) ± SD 45 ± 7
Duration of lump (mo) ± SD 30 ± 10
Menstrual status
Premenopausal 16 (64)
Postmenopausal 9 (36)
Size of lump 10.5 ± 5 cm
Recurrence (n= 9)
Once 5 (20)
Twice 3 (12)
Thrice 1 (4)
FNAC diagnosis
Phyllodes 18 (72)
Fibroadenoma 2 (8)
Epithelial hyperplasia 2 (8)
Fibroadenosis 2 (8)
Ductal carcinoma 1 (4)
Histopathology
Benign 7 (28)
Borderline 5 (20)
Malignant 13 (52)
SD = standard deviation; FNAC = fine needle aspiration cytology.
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Of the nine LEs, six procedures were performed at periph-
eral hospitals and three at our centre. The patient with
bilateral PT had bilateral WLEs performed on her. A sum-
mary of all the surgical procedures along with recurrence
rates after each procedure is provided in Table 2. Three
cases of malignant PT received adjuvant external irradia-
tion, but none of the patients received any form of sys-
temic therapy. Final histology was reported as benign in
seven, borderline in five and malignant in 13 cases.
The median follow-up duration was 4 years (range,
1–9 years). One patient with malignant PT died due 
to lung metastasis at 20 months following surgery and
another was lost to follow-up 15 months following sur-
gery. At the last hospital admission, the latter patient was
diagnosed as having liver and peritoneal metastases and
she declined any further treatment. The rest were all alive
with no evidence of disease at their last follow-up. Overall,
nine (36%) cases suffered from local recurrence, and four
(16%) cases experienced more than one recurrence. Overall,
the median time for noticing the first recurrence was 
6 months (range, 2 months to 5 years). According to his-
tology type, the median time to recurrence was 11 months
(range, 5–60 months), 5 months (range, 2–42 months)
and 8.5 months (range, 4–35 months) respectively in
benign, borderline and malignant PT. One patient with
benign PT suffered from three recurrences before she
finally underwent simple mastectomy. She was last seen
60 months following simple mastectomy and did not
experience any further recurrence. In two cases, the recur-
rent tumours were of higher grades than the primary
tumours (benignborderline; borderlinemalignant).
In the other cases, these were of the same grades as the 
primary tumours.
As a primary procedure, WLE and procedures of
higher magnitude were associated with no recurrence, and
LE was associated with a 100% risk of recurrence. As is 
evident from Table 2, irrespective of pathology type, the 
six patients who had WLE as their initial surgery had 
no recurrence in the follow-up period. Therefore, WLE
seems to be an adequate primary surgical procedure for
managing all PTs. However, the same does not seem to be
true for recurrent tumours because 50% of such patients
experienced further recurrence following WLE. None 
of the patients who underwent mastectomies either as
primary or secondary interventions had any recurrences.
Therefore, it is fair to state that patients in whom simple
mastectomy is performed are unlikely to suffer from fur-
ther recurrence. Clinicopathological comparison of recur-
rent and non-recurrent cases is provided in Table 3. The
extent of the surgical procedure was significantly associ-
ated with recurrence (p = 0.008). All cases subjected to LE
had recurrence, while those who had WLE or other proce-
dures of greater magnitude did not. Apart from this,
other factors were not significantly different between the
two groups. Even the type of pathology did not differ 
significantly between the two groups (p = 0.51).
Discussion
The clinical course of PT is unpredictable and is com-
monly marked by a high incidence of local recurrence and
unpredictable distant metastases.1–3 PT has a unique
blend of stromal and epithelial tissue components and
the stromal component predominantly determines the
overall behaviour of the tumour. In order to classify the
tumour as benign or malignant, numerous criteria have
been proposed, and the one proposed by Azzopardi4 and
Salvadori et al5 are widely followed. However, all the exis-
tent classifications fail in accurately predicting the clini-
cal behaviour and outcome of PT.6,7 Although in most of
the reported series, benign PT seems less prone to recur-
rence than the malignant types, it is difficult to predict
Table 2. Surgical procedures performed for primary and recurrent tumours
Surgical procedure
I Procedure 
Recurrence (%)
II Procedure 
Recurrence (%)
III Procedure 
n (%) n (%) n (%)
SE 9 (36) 100 1 (11.1) 100 −
WLE 6 (24) – 6 (66.7) 50 2 (50)†
SM 8 (32) – 1 (11.1)* – 1 (25)
MRM 2 (32) – 1 (11.1)* – 1 (25)
*Latissimus dorsi flap reconstruction was also performed; †one of these cases had further recurrence and a simple mastectomy was performed
on her. SE = simple excision; WLE = wide local excision; SM = simple mastectomy; MRM = modified radical mastectomy.
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recurrence in an individual case.2 The local recurrence rate
was 36% in the current study, which corresponds to the
reported rate in the literature ranging from 6% to 40%.1–3
Most of the recurrences in our patients occurred within
the first year. The mean age of patients in our study group
was 45 years, consistent with other reports in the litera-
ture.2,7,8 Though subclassification into benign, borderline
or malignant types could not be done, 72% of patients
could be preoperatively diagnosed as having PT on FNAC.
This rate is higher than the reported average rate in the
literature, which is 12–77%.9,10 This fact can be attributed
to the certain bias in the 24% of cases presenting with
locally recurrent tumours, where there was a high degree
of clinical suspicion for PT. A definite diagnosis is obvi-
ously critical for the adequate surgical management 
of PT. However, the diagnosis cannot be established with
certainty in a significant proportion of these cases.
Therefore, Jacklin et al suggested that all fibroadenoma
of the breast should be considered as possible PT until
proven otherwise, and if the index of suspicion is high, a
core biopsy should be performed before planning the sur-
gery.10 This approach seems effective in preventing local
recurrences but the same cannot be said about its cost
effectiveness.
The incidence of malignant PT among all PT cases
widely varies from 1.9% to 48.2%.2,6 In our study, it was
52%. One possible explanation for such a disparity is that 
while subclassifying these tumours, different workers used
different criteria. Various attempts to correlate tumour
recurrence with different clinicopathological criteria have
resulted in mixed outcomes. Of the various factors stud-
ied, much emphasis has been placed on tumour size and
histology type. Reinfuss et al found that the histological
type of PT was the only prognostic factor of the rate of
recurrence in their study. The local recurrence rate in their
series was 4.3%, 15.8% and 11.9% in patients with benign,
borderline and malignant PT respectively.1 Contrastingly,
Bennett et al did not find any significant differences in
recurrence rate among patients with benign (21%) and
malignant PT (18%),2 although they observed that malig-
nant tumours tended to recur earlier compared to benign
tumours. They also observed that tumours with infiltrat-
ing margins and large tumours were the ones likely to
recur. Interestingly, in a report by Hadju et al, a higher
local recurrence rate (18%) was seen in benign lesions than
in malignant lesions (8%).3 They attributed this finding
to a more radical surgical procedure adopted for malig-
nant PT as compared to their benign counterparts. This
observation strengthens our own finding that irrespective
of tumour characteristics, the extent of the surgical 
procedure is more significant in determining and/or pre-
venting local recurrence. The long-term overall survival of
patients with PT is determined by distant metastases.
Metastases are mostly reported in cases with malignant
Table 3. Comparison of recurrent and non-recurrent cases
Clinicopathologic features Non-recurrent cases (n= 16) Recurrent cases (n= 9) p
Age (yr) 43 ± 9.5 46 ± 8 0.161
Menstrual status 0.95
Premenopausal 10 (63%) 6 (67%)
Postmenopausal 6 (37%) 3 (33%)
Duration of lump (mo) 28 ± 10 31 ± 12 0.24
Size of lump (cm) 10.5 ± 5 9.5 ± 4 0.06
Histopathology 0.51
Benign 4 (25%) 3 (23%)
Borderline 3 (19%) 2 (33%)
Malignant 9 (56%) 4 (44%)
Initial surgical procedure 0.008
Excision – 9 (100%)
Wide local excision 6 (37.5%) –
Simple mastectomy 8 (50%) –
MRM 2 (12.5%) –
MRM = modified radical mastectomy.
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and borderline tumours, and rarely in benign types. The
reported incidence of distant metastases ranges from 25%
to 48%.2,11 In our series, two patients (15%) with malig-
nant PT developed metastases; the incidence may increase
with further long-term follow-up of our cases.
Surgery is the mainstay of treatment for PT. However,
due to the relative rarity of the tumour, and heterogene-
ity of procedures applied for managing these by various
centres, no definite conclusion regarding the appropriate
surgical procedure can be drawn. Since PTs are rarely mul-
tifocal, WLE is currently being suggested to be an appro-
priate primary surgical procedure for all the histological
types of PT.1–3 Mastectomy seems to be reserved for cases
where the tumour is large enough to allow a safe and cos-
metically acceptable WLE procedure, although some
advocate mastectomy for all malignant PTs.2,5 Since the
incidence of axillary lymph node metastases in malignant
PT is less than 0.5%, axillary lymph node dissection is 
not routinely recommended and rarely needed.1,2 No
form of adjuvant therapy has been shown to be effective
in preventing local recurrence and distant metastases.
According to published literature, radiotherapy and
chemotherapy fail to improve the clinical outcome of PT,
though obviously the experience is limited and no defi-
nite conclusion can be drawn from these reports.12,13 Use
of doxorubicin, cisplatin and etoposide have resulted in
some benefit in the management of patients with visceral
metastases.14,15
In conclusion, in our study none of the clinicopatho-
logical factors except the extent of the surgical procedure
significantly affected the rate of local recurrence. WLE
seemed to be an adequate initial surgical procedure for all
patients with PT. Mastectomy should be reserved for
recurrent or large tumours where WLE cannot be safely
performed. Since recurrences are largely unpredictable,
long-term follow-up of these patients is mandatory. Further
collaborative studies are needed to define the exact role of
adjuvant therapy in the management of malignant PT.
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